SpringerLink
Log in

Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells

  • ORIGINAL ARTICLE
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

This study mainly explored the role of lncRNA miR503HG in multiple myeloma and the potential downstream regulatory mechanism affecting disease. Real-time quantitative polymerase chain reaction was used to measure the expression levels of miR503HG and miR-103. A cell counting kit-8 assay was performed to detect cell viability. The concentrations of adhesion-related factors (MUC-1, VCAM-1, ICAM-1) were determined using enzyme-linked immunosorbent assay. The targeting relationship between miR503HG and miR-103 was detected by dual-luciferase reporter assay. The miR503HG expression in peripheral blood of multiple myeloma patients was lower than that of normal healthy individuals and associated with ISS stage and worse overall survival. miR-103 was identified as the downstream target of miR503HG. Upregulation of miR503HG could inhibit cell proliferation and adhesion of multiple myeloma cell lines, which could partially reverse the inhibition of adhesion and proliferation by high expression of miR-103. lncRNA miR503HG expression was downregulated in multiple myeloma and had potential diagnostic/prognostic value. MiR503HG exerts a molecular sponge effect on miR-103 and affects its expression, thus achieving the inhibitory effect on multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Sun WJ, Zhang JJ, An N, Shen M, Huang ZX, Li X (2016) Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. J Int Med Res 44(6):1462–1473. https://doi.org/10.1177/0300060516664820

    Article  PubMed  PubMed Central  Google Scholar 

  2. Spaan I, Raymakers RA, van de Stolpe A, Peperzak V (2018) Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol 11(1):67. https://doi.org/10.1186/s13045-018-0615-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ge Q, Wang Y, Zhu H, Xu K, Sheng L, Yan X et al (2022) Gastrointestinal bleeding secondary to high-dose melphalan pretreatment in patients with multiple myeloma was associated with the mode of melphalan administration. Evid Based Complementary Altern Med 2022:2088217. https://doi.org/10.1155/2022/2088217

    Article  Google Scholar 

  4. Bridges MC, Daulagala AC, Kourtidis A (2021) LNCcation: lncRNA localization and function. J Cell Biol. https://doi.org/10.1083/jcb.202009045

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fanelli GN, Gasparini P, Coati I, Cui R, Pakula H, Chowdhury B et al (2018) Long-Noncoding RNAs in gastroesophageal cancers. Non-coding RNA Res 3(4):195–212. https://doi.org/10.1016/j.ncrna.2018.10.001

    Article  CAS  Google Scholar 

  6. Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB, Gupta SC (2021) Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Biophys Acta Rev Cancer 1875(2):188502. https://doi.org/10.1016/j.bbcan.2021.188502

    Article  CAS  PubMed  Google Scholar 

  7. Zhang D, Du D, Yi S, Li X (2020) LncRNA PCAT6: a potential biomarker for diagnosis and prognosis of bladder cancer. Ann Diagn Pathol 49:151642. https://doi.org/10.1016/j.anndiagpath.2020.151642

    Article  PubMed  Google Scholar 

  8. Zhang G, Fan E, Zhong Q, Feng G, Shuai Y, Wu M et al (2019) Identification and potential mechanisms of a 4-lncRNA signature that predicts prognosis in patients with laryngeal cancer. Hum Genomics 13(1):36. https://doi.org/10.1186/s40246-019-0230-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hu Y, Lin J, Fang H, Fang J, Li C, Chen W et al (2018) Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia 32(10):2250–2262. https://doi.org/10.1038/s41375-018-0104-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gao Y, Fang P, Li WJ, Zhang J, Wang GP, Jiang DF et al (2020) LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7–H3 in multiple myeloma. Mol Immunol 117:20–28. https://doi.org/10.1016/j.molimm.2019.10.026

    Article  CAS  PubMed  Google Scholar 

  11. Yang LH, Du P, Liu W, An LK, Li J, Zhu WY et al (2021) LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma 68(4):788–797. https://doi.org/10.4149/neo_2021_210205N184

    Article  CAS  PubMed  Google Scholar 

  12. Tian J, Yang L, Wang Z, Yan H (2022) MIR503HG impeded ovarian cancer progression by interacting with SPI1 and preventing TMEFF1 transcription. Aging 14(13):5390–5405. https://doi.org/10.18632/aging.204147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hu YL, Zhang YX, Liu N, Liu H, Yuan YC (2021) LncRNA MIR503HG regulated cell viability, metastasis and apoptosis of cervical cancer via miR-191/CEBPB axis. Eur Rev Med Pharmacol Sci 25(8):3200–3210. https://doi.org/10.26355/eurrev_202104_25728

    Article  PubMed  Google Scholar 

  14. Xu S, Zhai S, Du T, Li Z (2020) LncRNA MIR503HG inhibits non-small cell lung cancer cell proliferation by inducing cell cycle arrest through the downregulation of cyclin D1. Cancer Manag Res 12:1641–1647. https://doi.org/10.2147/cmar.S227348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fu J, Dong G, Shi H, Zhang J, Ning Z, Bao X et al (2019) LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med 23(7):4738–4745. https://doi.org/10.1111/jcmm.14344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Li Z, Kumar S, ** DY, Calin GA, Chng WJ, Siu KL et al (2020) Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. J Clin Lab Anal 20:403. https://doi.org/10.1186/s12935-020-01504-4

    Article  CAS  Google Scholar 

  17. **ao G, Li Y, Wang Y, Zhao B, Zou Z, Hou S et al (2018) LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. Cancer Cell Int 370(2):254–263. https://doi.org/10.1016/j.yexcr.2018.06.026

    Article  CAS  Google Scholar 

  18. Xu H, Yin Q, Shen X, Ju S (2020) Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma. Ann Hematol 99(9):2159–2171. https://doi.org/10.1007/s00277-020-04161-9

    Article  CAS  PubMed  Google Scholar 

  19. Zhao P, Zhao X (2021) Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients. Ann Hematol 35(11):23924. https://doi.org/10.1002/jcla.23924

    Article  CAS  Google Scholar 

  20. Zhong Y, Liu Z, Li D, Liao Q, Li J (2020) Identification and validation of a potential prognostic 7-lncRNA signature for predicting survival in patients with multiple myeloma. BioMed Res Int 2020:3813546. https://doi.org/10.1155/2020/3813546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Meng H, Han L, Hong C, Ding J, Huang Q (2018) Aberrant lncRNA expression in multiple myeloma. Oncol Res 26(5):809–816. https://doi.org/10.3727/096504017x15123872205507

    Article  PubMed  PubMed Central  Google Scholar 

  22. Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH et al (2014) MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer 14:809. https://doi.org/10.1186/1471-2407-14-809

    Article  PubMed  PubMed Central  Google Scholar 

  23. Liu N, Feng S, Li H, Chen X, Bai S, Liu Y (2020) Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis. J Cancer Res Clin Oncol 146(2):367–379. https://doi.org/10.1007/s00432-020-03127-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ronchetti D, Todoerti K, Vinci C, Favasuli V, Agnelli L (2020) Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma. Cancers. https://doi.org/10.3390/cancers12040782

    Article  PubMed  PubMed Central  Google Scholar 

  25. Monteiro JP, Rodor J, Caudrillier A, Scanlon JP, Spiroski AM, Dudnakova T et al (2021) MIR503HG loss promotes endothelial-to-mesenchymal transition in vascular disease. Circ Res 128(8):1173–1190. https://doi.org/10.1161/circresaha.120.318124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Qiu F, Zhang MR, Zhou Z, Pu JX, Zhao XJ (2019) lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelial-mesenchymal transition in bladder cancer. J Cell Biochem 120(6):10821–10829. https://doi.org/10.1002/jcb.28373

    Article  CAS  PubMed  Google Scholar 

  27. Lin H, Wang J, Wang T, Wu J, Wang P, Huo X et al (2021) The LncRNA MIR503HG/miR-224-5p/TUSC3 signaling cascade suppresses gastric cancer development via modulating ATF6 branch of unfolded protein response. Front Oncol 11:708501. https://doi.org/10.3389/fonc.2021.708501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Han H, Li H, Zhou J (2020) Long non-coding RNA MIR503HG inhibits the proliferation, migration and invasion of colon cancer cells via miR-107/Par4 axis. J Cell Mol Med 395(2):112205. https://doi.org/10.1016/j.yexcr.2020.112205

    Article  CAS  Google Scholar 

  29. Ren D, Cai Y, Xu G (2020) Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients. Transl Cancer Res 9(3):1495–1505. https://doi.org/10.21037/tcr.2020.01.41

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Hematology, Affiliated Hospital of Gansu Medical College, No. 296, Kongtong East Road, Kongtong District, **liang, Gansu, 744000, China

    **ling Yin & **ang Zhou

Authors
  1. **ling Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **ang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to **ling Yin or **ang Zhou.

Ethics declarations

Conflict of interest

There is no conflict of interest in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, P., Zhou, X. Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells. Indian J Hematol Blood Transfus 40, 43–51 (2024). https://doi.org/10.1007/s12288-023-01658-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-023-01658-x

Keywords

Search

Navigation